Skip to content

Effect of Qizhijiangtang Capsule on treating Non-Proliferative Diabetic Retinopathy

Effect of Qizhijiangtang Capsule on treating Non-Proliferative Diabetic Retinopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023506
Enrollment
Unknown
Registered
2019-05-31
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Proliferative Diabetic Retinopathy

Interventions

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to WHO criteria in 1999, meet the diagnosis of type 2 diabetes mellitus; 2. Meet the diagnosis of diabetic retinopathy, and the retinopathy is at non-proliferative phase; 3. Pattern differentiation of TCM is deficiency of qi and yin and blood stasis; 4. Aged 30-70 years; 5. Have signed the informed consent; 6. Hypoglycemic drugs have been used steadily in the past three months and can be expected to remain unchanged throughout the study.

Exclusion criteria

Exclusion criteria: 1. Postoperative retinal photocoagulation, suitable photocoagulation therapy, diabetic retinopathy patients with proliferative stage of diabetic retinopathy (IV, V, VI stage), diabetic retinopathy patients with type 1 diabetes mellitus, patients with other eye diseases (e.g. glaucoma, cataracts that significantly affect fundus examination, non-diabetic retinopathy, uveitis, retinal detachment) Optic nerve diseases and high myopia with fundus diseases, etc. 2. Those with serious complications of heart, lung, liver, kidney and brain or with other serious primary diseases; 3. Recurrent hypoglycemia, diabetic ketosis, ketoacidosis and severe infections in recent months; 4. If the systolic blood pressure is greater than 160 mmHg or (and) the diastolic blood pressure is greater than 100 mmHg after uncontrolled or controlled blood pressure; 5. Diabetic nephropathy occurs in renal failure (azotemia, uremia); 6. Pregnant, pregnant or lactating women, or those with a history of drug allergy; 7. Psychiatric patients; 8. Patients with impaired liver and kidney function (ALT and AST were 2 times higher than the upper limit of normal value, and serum creatinine was higher than the upper limit of normal value). 9. Alcohol abuse and/or psychoactive substances, drug abusers and addicts in the past five years; 10. According to the judgement of the researcher, other pathological changes or situations that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment, unstable living environment and so on, are liable to lead to lost visits; 11. Allergic to any component of Qizhi Jiangtang Capsule.

Design outcomes

Primary

MeasureTime frame
fundus photography;fundus fluorescein angiography;

Secondary

MeasureTime frame
routine ophthalmological examination;fasting blood glucose;2h postprandial blood glucose;glycosylated hemoglobin;Blood lipids;urine albumin excretion ratio;TCM symptoms;

Countries

China

Contacts

Public ContactNi Qing

Guang'anmen Hospital, China Academy of Chinese Medicine

niqing669@163.com+86 13701253942

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026